[go: up one dir, main page]

ES2149451T3 - Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido. - Google Patents

Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido.

Info

Publication number
ES2149451T3
ES2149451T3 ES96903340T ES96903340T ES2149451T3 ES 2149451 T3 ES2149451 T3 ES 2149451T3 ES 96903340 T ES96903340 T ES 96903340T ES 96903340 T ES96903340 T ES 96903340T ES 2149451 T3 ES2149451 T3 ES 2149451T3
Authority
ES
Spain
Prior art keywords
alpha
hexahidrobenz
isoindol
adrenergic antagonists
substituted tricyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96903340T
Other languages
English (en)
Inventor
Michael D Meyer
Robert J Altenbach
Fatima Z Basha
William A Carroll
Irene Drizin
James F Kerwin Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2149451T3 publication Critical patent/ES2149451T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE W ES UN ANILLO TRICICLICO HETEROCICLICO, EL CUAL ES UN ANTAGONISTA {AL}-1 ADRENERGICO Y ES UTIL EN EL TRATAMIENTO DE BPH; TAMBIEN SE REVELAN LAS COMPOSICIONES {AL}-1 ANTAGONISTAS Y UN METODO PARA ANTAGONIZAR A LOS RECEPTORES {AL}-1 Y TRATAR EL BPH.
ES96903340T 1995-01-27 1996-01-11 Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido. Expired - Lifetime ES2149451T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37941495A 1995-01-27 1995-01-27
US08/463,528 US5597823A (en) 1995-01-27 1995-06-05 Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists

Publications (1)

Publication Number Publication Date
ES2149451T3 true ES2149451T3 (es) 2000-11-01

Family

ID=27008615

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96903340T Expired - Lifetime ES2149451T3 (es) 1995-01-27 1996-01-11 Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido.

Country Status (15)

Country Link
US (1) US5597823A (es)
EP (1) EP0808318B1 (es)
JP (1) JP2001504797A (es)
KR (1) KR19980701700A (es)
AT (1) ATE194141T1 (es)
AU (1) AU705283B2 (es)
CA (1) CA2211212A1 (es)
DE (1) DE69609051T2 (es)
DK (1) DK0808318T3 (es)
ES (1) ES2149451T3 (es)
GR (1) GR3034485T3 (es)
IL (1) IL116405A (es)
MX (1) MX9705674A (es)
PT (1) PT808318E (es)
WO (1) WO1996022992A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AR008395A1 (es) * 1996-07-09 2000-01-19 Astra Pharma Prod Compuesto derivado de pirimidina, composicion farmaceutica que lo comprende, procedimiento para prepararlo, y compuesto intermediario util parallevar a cabo dicho procedimiento.
US5891882A (en) * 1996-12-06 1999-04-06 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine α-1 adenergic compounds
CA2294590A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP3453362B2 (ja) * 1998-08-20 2003-10-06 富山化学工業株式会社 含窒素複素環カルボキサミド誘導体またはその塩並びにそれらを含有する抗ウイルス剤
EP1115710A1 (en) * 1998-08-20 2001-07-18 Abbott Laboratories Process for preparing regiospecific substituted pyrazine isomers
BR9916845A (pt) * 1998-12-24 2001-10-30 Aventis Pharm Prod Inc Compostos de (aminoiminometil ouaminometil)benzo-heteroarila substituìdos
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
JP2005104838A (ja) * 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
US7524853B2 (en) * 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
WO2006063615A1 (en) * 2004-12-13 2006-06-22 Solvay Pharmaceuticals Gmbh NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE
US7465739B2 (en) * 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
US7654956B2 (en) 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
RU2409581C2 (ru) * 2004-12-13 2011-01-20 Зольвай Фармасьютиклз Гмбх НОВЫЕ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ТИОФЕНПИРИМИДИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
JP5237798B2 (ja) 2005-06-23 2013-07-17 アレイ バイオファーマ、インコーポレイテッド ベンズイミダゾール化合物の調製方法
EP1948656A2 (en) * 2005-11-03 2008-07-30 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-a2 inhibitors
JP5041403B2 (ja) * 2007-02-02 2012-10-03 国立大学法人北海道大学 カフェイン類縁体
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
MX2015009444A (es) 2013-01-25 2016-04-15 Aldeyra Therapeutics Inc Trampas novedosas en el tratamiento de la degeneracion macular.
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
ES2968462T3 (es) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Sal polimórfica de 6-cloro-3-amino-2(2-hidroxiprolil) quinolina y usos de la misma
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN112079832A (zh) * 2020-10-30 2020-12-15 黑龙江中医药大学 一种治疗子宫肌瘤的药物及其制备方法
CN114957090B (zh) * 2021-12-31 2023-09-19 淮阴师范学院 稠合异吲哚衍生物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
GB9123857D0 (en) * 1991-11-09 1992-01-02 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU705283B2 (en) 1999-05-20
GR3034485T3 (en) 2000-12-29
DK0808318T3 (da) 2000-10-16
ATE194141T1 (de) 2000-07-15
EP0808318B1 (en) 2000-06-28
AU4745796A (en) 1996-08-14
IL116405A0 (en) 1996-03-31
EP0808318A1 (en) 1997-11-26
DE69609051D1 (de) 2000-08-03
PT808318E (pt) 2000-12-29
KR19980701700A (ko) 1998-06-25
MX9705674A (es) 1997-10-31
US5597823A (en) 1997-01-28
CA2211212A1 (en) 1996-08-01
JP2001504797A (ja) 2001-04-10
WO1996022992A1 (en) 1996-08-01
IL116405A (en) 2001-09-13
DE69609051T2 (de) 2001-03-22

Similar Documents

Publication Publication Date Title
ES2149451T3 (es) Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido.
ES2159721T3 (es) Antagonistas alfa-1-adrenergicos biciclicos sustituidos de hexahidrobenz(e)isoindol.
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
RU2012110522A (ru) Гипотензивная комбинация валсартана и блокатора кальциевых каналов
DK0565634T3 (da) Angiotensin-II-receptorblokkersammensætninger
ATE204857T1 (de) Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
ATE187963T1 (de) Neue 4-piperidinyl substituierte lactame als neukokinin 2 rezeptor antagonisten zur behandlung von asthma
ATE305781T1 (de) Non-peptidische vasopressin via antagonisten
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
TR199901883T2 (xx) Benzopiranopirol ve benzopiranopiridin alfa-1 adrenerjik bile�ikleri.
AU1198897A (en) 1-benzenesulfonyl pyrrolidine derivatives as bradykinin receptor antagonists
DE69819166D1 (de) 8-substituierte-9h-1,3-dioxolo/4,5-h//2,3/benzodiazepin derivate als ampa/kainate-rezeptor-hemmer
AU5644296A (en) Novel heterocyclic chemistry
DE69526452D1 (de) Indolditerpen alkaloide
ES2149984T3 (es) Derivados imidazolilalquilos de imidazol(5,1-c)(1,4)benzoxazin-1-ona y su utilizacion como agentes terapeuticos.
MY118704A (en) Process for preparation of eprosartan
EP2140862A3 (en) Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
BR9713682A (pt) Compostos alfa - 1 adrenergicos de benzopiranopirrol e benzopiranopiridina
NO981188L (no) 5-HT3-reseptorantagonister for dyskinesi
DE69903930D1 (de) N-aryloxyethyl-indolyl-alkylamine zur behandlung von depressionen
BG100531A (bg) Метод за инхибиране на фоторазлагането на 3-заместени 2-оксиндоли

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 808318

Country of ref document: ES